Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV 16-associated tumours with gemcitabine

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1683-1689

  Mikyšková, Romana ^a   Indrová, Marie ^a   Šímová, Jana ^a   Bieblová, Jana ^a   Bubeník, Jan ^a   Reiniš, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Cellular vaccines; Chemoimmunotherapy; Gemcitabine; Human papilloma virus; Interleukin 12; Lung metastases

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GEMCITABINE; GENETICALLY MODIFIED TUMOR VACCINE; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE THERAPY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL SEPARATION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMAN PAPILLOMAVIRUS 16; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS INFECTIONS;

EID: 79954530059     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1221     Document Type: Article

References (35)

1. Nowak AK, Lake RA and Robinson BW: Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Re 1: 975-990, 2006.
2. Ramakrishnan R, Antonia S and Gabrilovich DI: Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 57: 1523-1529, 2008.
3. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA and Robinson BW: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905-4913, 2003. (Pubitemid 36554719)
4. Bubeník J: Genetically modified vaccines augment the efficacy of cancer surgery and chemotherapy. Folia Biol (Praha) 55: 199-200, 2009.
5. Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E and Reinis M: Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 28: 253-259, 2006.
6. Indrová M, Bubeník J, Mikysková R, Mendoza L, Símová J, Bieblová J, Jandlová T, Jinoch P, Smahel M, Vonka V and Pajtasz-Piasecka E: Chemoimmunotherapy in mice carrying HPV-16 associated, MHC class I and MHC class I tumours: effects of CBM-M potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 22: 691-695, 2003.
7. Indrova M, Bieblova J, Bubenik J and Reinis M: IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32: 499-507, 2008. (Pubitemid 351188317)
8. Bubeník J and Šímová J: Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy. J BUON 14: 169-173, 2009.
9. Ménard C, Martin F, Apetoh L, Bouyer F and Ghiringhelli F: Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57: 1579-1587, 2008.
10. Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358, 2002. (Pubitemid 34411717)
11. Nowak AK, Robinson BW and Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496, 2003. (Pubitemid 36951021)
12. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001. (Pubitemid 32694981)
13. Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG, Matar P and Mazzolini G: A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res 15: 7256-7265, 2009.
14. Hui YF and Reitz J: Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54: 162-170, 1997. (Pubitemid 27058210)
15. Suzuki E, Sun J, Kapoor V, Jassar AS and Albelda SM: Gemcitabine has significant immunomodulatory activity in murine models independent of its cytotoxic effects. Cancer Biol Ther 6: 880-885, 2007. (Pubitemid 351574977)
16. Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy. Future Oncol 1: 7-17, 2005.
17. Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54: 915-925, 2005. (Pubitemid 40991334)
18. +/ CDlIb+ myeloid suppressor cells in tumor-bearirg animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721, 2005.
19. Liu WM, Fowler DW, Smith P and Dalgleish AG: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102: 115-123, 2010.
20. Le HK, Graham L, Cha E, Morales JK, Manjili MH and Bear HD: Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9: 900-909, 2009.
21. Sinha P, Clements VK, Bunt SK, Albelda SM and Ostrand-Rosenberg S: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983, 2007.
22. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA and Palleroni AV: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993. (Pubitemid 23277355)
23. Nanni P, Rossi I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP and Lollini PL: Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 58: 1225-1230, 1998. (Pubitemid 28183212)
24. Vagliani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, Forni G and Colombo MP: Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 56: 467-470, 1996. (Pubitemid 26043641)
25. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP and Forni G Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89: 1049-1058, 1997. (Pubitemid 27327870)
26. Bubenik J: Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets 8: 180-186, 2008.
27. Portielje JE, Gratama JW, van Ojik HH, Stoter G and Kruit WH: IL-12: a promising adjuvant for cancer vaccination (review). Cancer Immunol Immunother 52: 133-144, 2003. (Pubitemid 36384713)
28. Colombo MP and Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168, 2002.
29. Indrová M, Bieblová J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubeník J and Reinis M: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 34: 173-179, 2009.
30. Imagawa Y, Satake K, Kato Y, Tahara H and Tsukuda M: Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model. Auris Nasus Larynx 31: 239-245, 2004. (Pubitemid 39214990)
31. Mikysková R, Bubenik J, Mendoza L, Vonka V, Smahel M, Símová J and Jandlová T: Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin Exp Metastasis 18: 581-587, 2000.
32. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996. (Pubitemid 26010379)
33. Smahel M, Sima P, Ludvikova V, Marinov I, Pokorna D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003. (Pubitemid 36142051)
34. Vlk V, Rössner P, Indrova M, Bubenik J and Sobota V: Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer 76: 115-119, 1998. (Pubitemid 28164577)
35. Mikysková R, Bubeník J, Vonka V, Smahel M, Indrova M, Bieblová J, Símová J and Jandlová T: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol 26: 521-527, 2005.